Welcome to our dedicated page for Scholar Rock Holding news (Ticker: SRRK), a resource for investors and traders seeking the latest updates and insights on Scholar Rock Holding stock.
Scholar Rock Holding Corporation (SRRK) is a biotechnology company dedicated to pioneering a novel class of biologic therapies known as 'niche modulators'. These therapies selectively target the activation of growth factors within the disease microenvironment, offering a groundbreaking approach to treating serious medical conditions. Scholar Rock's initial proprietary and partnered drug discovery programs focus on specific growth factors, particularly members of the TGF-beta superfamily, which are critical in regulating cell growth and differentiation. These growth factors are notably present in the microenvironments of significant diseases like fibrosis, musculoskeletal disorders, and autoimmune diseases.
The company’s innovative therapeutic strategy stems from the foundational scientific discoveries of its founders, Professors Timothy Springer, PhD, and Leonard Zon, MD, from Children's Hospital Boston and Harvard Medical School. These discoveries illuminate the molecular mechanisms of growth factor activation, empowering Scholar Rock to advance its ground-breaking treatments.
Scholar Rock is backed by a consortium of top-tier life sciences investors, including Polaris Partners and Arch Venture Partners. Its flagship product candidate, Apitegroma, is a selective, fully human, monoclonal antibody that inhibits the activation of the growth factor myostatin in skeletal muscle. This innovative mechanism holds promise for treating neuromuscular disorders. Another key product in the company's pipeline is SRK-181, which targets the activation of latent transforming growth factor beta-1 (TGFβ1) and is being developed to treat cancers that are resistant to existing anti-PD-(L)1 antibody therapies.
With its operations based in the United States, Scholar Rock continues to make significant strides in the biopharmaceutical industry, pushing the envelope of medical science and offering hope for effective treatments against some of the most challenging diseases.
Scholar Rock (NASDAQ: SRRK) presented new data from its Phase 1 DRAGON trial of SRK-181, a selective inhibitor of latent TGFβ1 activation, in combination with pembrolizumab at the ASCO 2024 Annual Meeting. The study showed promising objective response rates (ORR) in various tumor types for patients resistant to anti-PD-(L)1 therapies. Clear cell renal cell carcinoma (ccRCC) patients exhibited a doubling of the ORR, suggesting a potential patient selection strategy. SRK-181 was generally well tolerated, with no Grade 5 treatment-related adverse events. These findings bolster confidence in SRK-181's ability to overcome immune checkpoint inhibitor-associated resistance. Scholar Rock plans to discuss these results further with the FDA.
Scholar Rock (NASDAQ: SRRK) will present new data from the Phase 1 DRAGON trial of SRK-181 in combination with pembrolizumab at the ASCO Annual Meeting, May 31 – June 4 in Chicago. The trial demonstrated encouraging responses and tolerability in patients with advanced solid tumors, including ccRCC, HNSCC, melanoma, and UC. It also showed that the SRK-181 + pembrolizumab combination improved the proinflammatory microenvironment. A positive correlation between CD8+ T cell infiltration and response rate was observed in ccRCC patients. An oral presentation of the data is scheduled for June 3 at 1:50 p.m. CDT, followed by a conference call on June 4 at 8 a.m. EDT.
Scholar Rock (NASDAQ: SRRK) has initiated the Phase 2 EMBRAZE trial to evaluate the efficacy and safety of apitegromab in preserving lean muscle mass in obese individuals on GLP-1 receptor agonist therapy. The trial involves 100 participants and will last 24 weeks, with primary results expected by mid-2025.
New preclinical data revealed SRK-439's superior performance over anti-ActRII antibodies in preserving lean mass in diet-induced obesity mice. SRK-439 showed significant lean mass preservation at lower doses compared to anti-ActRII, indicating its potential as a best-in-class treatment for obesity-related muscle mass preservation.
The company shared these findings at an Investor Event, emphasizing the advantage of selective latent myostatin inhibition. Future data presentations and an anticipated IND filing for SRK-439 in 2025 are planned.
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company, announced its participation in several upcoming investor conferences in June. The events include: UBS Obesity Therapeutics Day on May 23 at 9:00 a.m. ET, Jefferies Global Healthcare Conference on June 6 at 2:00 p.m. ET in New York City, and the 45th Annual Goldman Sachs Global Healthcare Conference on June 13 at 9:20 a.m. ET in Miami, Florida. These conferences will feature various presentations and virtual chats, with live webcasts available on Scholar Rock's website and archived for replay for approximately 90 days.
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company, has announced inducement equity awards under Nasdaq Listing Rule 5635(c)(4).
The awards cover an aggregate of 102,150 shares, including 58,370 stock options and 43,780 restricted stock units. These grants are part of Scholar Rock's 2022 Inducement Equity Plan, aimed at attracting new talent.
The stock options have an exercise price of $13.64, with vesting schedules based on employee service. This news is part of Scholar Rock's ongoing efforts to advance treatments for serious diseases.
Scholar Rock (NASDAQ: SRRK) will host an Investor Day on May 22, 2024, starting at 8:30 a.m. ET in New York City. The event will feature presentations from the executive management team on their myostatin inhibition programs targeting spinal muscular atrophy (SMA) and obesity. Renowned experts Dr. Ania Jastreboff of Yale School of Medicine and Dr. Diana Castro of the Neurology & Neuromuscular Care Center will also provide insights. Participants can access a live webcast and slide presentation via Scholar Rock's website, with a replay available for 90 days.
Scholar Rock, a late-stage biopharmaceutical company focused on innovative treatments for SMA and cardiometabolic disorders, reported Q1 2024 financial results. They are on track to report Phase 3 SAPPHIRE trial data in Q4 2024. Initiating Phase 2 trial for apitegromab in obesity. Strong financial position with $238 million in cash. Positive clinical data presentations for SRK-181 and SRK-439.
FAQ
What is the current stock price of Scholar Rock Holding (SRRK)?
What is the market cap of Scholar Rock Holding (SRRK)?
What is Scholar Rock Holding Corporation's main focus?
What are niche modulators?
Who founded Scholar Rock?
What is Apitegroma?
What diseases does Scholar Rock target?
What is SRK-181?
Who are some of Scholar Rock's investors?
Where is Scholar Rock based?
What is the therapeutic approach of Scholar Rock?
What recent achievements has Scholar Rock made?
